News | SNMMI | July 14, 2020

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the cont

Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the contralateral, asymptomatic side of the neck has an SUVmax = 0.7. This result encouraged a surgeon to explore the area. The surgeon ultimately found a collection of small arteries wrapped around the nerve in this location. The small arteries underwent lysis by the surgeon and the patient reported tremendous relief of symptoms. (A) Coronal thick slab MIP of 18F-FDG PET. (B) Axial LAVA FLEX MRI through the cervical spine. (C) Axial PET at the same slice as the axial MRI. (D) Fused axial PET/MRI. Image courtesy of Cipriano, et al., Stanford University, CA.

July 14, 2020 — A new molecular imaging approach utilizing 18F-FDG positron emission tomography (PET) and magnetic resonance imaging (MRI) can precisely identify the location of pain generators in chronic pain sufferers, often precipitating a new management plan for patients. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.

Pain is the most common reason to seek medical attention, and those who suffer from it outnumber those who suffer from cancer, heart disease and diabetes combined. According to the National Center for Complementary and Integrative Health, chronic pain affects nearly 50 million adults in the United States and costs the nation's healthcare system as much as $635 billion in total expenses, including imaging and treatment costs.

"In the past few decades, we have confirmed that anatomic-based imaging approaches, such as conventional MRI, are unhelpful in identifying chronic pain generators," said Sandip Biswal, M.D., musculoskeletal radiologist and associate professor of radiology at Stanford University School of Medicine in Stanford, California. "We know that 18F-FDG PET has the ability to accurately evaluate increased glucose metabolism that arises from to acute or chronic pain generators. As such, in our study we examined PET/MRI as a potential solution to determine the exact molecular underpinnings of one's pain."

In the study, 65 chronic pain patients underwent 18F-FDG PET/MRI from head to foot. Maximum standardized uptake values and target-to-background ratios were measured using image analysis software. PET/MR images were evaluated by two radiologists to determine if increased 18F-FDG uptake occurred in the site of symptoms or in other areas of the body. Imaging results were then discussed with the referring physician, who determined whether a change in the pain management plan would follow.

Increased uptake of 18F-FDG in affected nerves and muscle was identified at the site of pain and other areas of the body in 58 out of 65 patients. This resulted in a mild modification of management plan (e.g., additional diagnostic test) for 16 patients and a significant modification for 36 patients (e.g., new invasive procedure suggested or ordered). In total, new management plans were implemented for 40 out of 65 patients, which had not been anticipated by the referring physician.

"The results of this study show that better outcomes are possible for those suffering from chronic pain," said Biswal. "This clinical molecular imaging approach is addressing a tremendous unmet clinical need, and I am hopeful that this work will lay the groundwork for the birth of a new subspecialty in nuclear medicine and radiology. Using this approach will require knowledge and expertise not only in nuclear medicine but also in musculoskeletal imaging, neuroradiology and potentially other fields, such as body imaging and pediatric radiology, where pain syndromes are important clinical problems."

For more information: www.snmmi.org

Related SNMMI20 Content:

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of
The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton

The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton

News | Nuclear Imaging | March 12, 2021
March 12, 2021 — Magnetic resonance imaging (MRI)
Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
News | Nuclear Imaging | March 08, 2021
March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) an
CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.

CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019. Photo by Dave Fornell.

Feature | Radiation Dose Management | March 04, 2021 | By Dave Fornell
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S.